Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement (Q39608912)

13 September 2017

Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement (English)

1 reference

13 September 2017

0 references

1 reference

lymphoblastic leukemia

1 reference

Aarthi Jayanthan

1

1 reference

13 September 2017

Andrea Incoronato

2

1 reference

13 September 2017

Anjali Singh

3

1 reference

13 September 2017

Christopher Blackmore

4

1 reference

13 September 2017

Delphine Bernoux

5

1 reference

13 September 2017

Victor Lewis

6

1 reference

13 September 2017

Ronald Stam

7

1 reference

13 September 2017

James A Whitlock

8

1 reference

13 September 2017

Aru Narendran

9

1 reference

13 September 2017

28 November 2010

1 reference

13 September 2017

Pediatric Blood Cancer

1 reference

13 September 2017

56

1 reference

13 September 2017

3

1 reference

13 September 2017

353-360

1 reference

Risk-adapted treatment of pediatric acute lymphoblastic leukemia

13 September 2017

1 reference

Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type.

21 January 2018

1 reference

Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.

21 January 2018

1 reference

The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs

21 January 2018

1 reference

Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.

21 January 2018

1 reference

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

21 January 2018

1 reference

Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.

21 January 2018

1 reference

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

21 January 2018

1 reference

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

21 January 2018

1 reference

Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation

21 January 2018

1 reference

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

21 January 2018

1 reference

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

21 January 2018

1 reference

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.

21 January 2018

1 reference

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity

21 January 2018

1 reference

ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway

21 January 2018

1 reference

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

21 January 2018

1 reference

Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene

21 January 2018

1 reference

A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcript

21 January 2018

1 reference

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

21 January 2018

1 reference

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

21 January 2018

1 reference

Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.

21 January 2018

1 reference

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.

21 January 2018

1 reference

Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress

21 January 2018

1 reference

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia

21 January 2018

1 reference

Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner

21 January 2018

1 reference

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

21 January 2018

1 reference

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

21 January 2018

1 reference

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts

21 January 2018

1 reference

Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)

21 January 2018

1 reference

The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7.

21 January 2018

1 reference

Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

21 January 2018

1 reference

A new acute lymphoblastic leukaemia cell line BEL-1 with t(4; 11) (q21; q23) chromosomal translocation and a unique aberrant p27 transcript

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.22760

1 reference

13 September 2017

1 reference